Operating through 125 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (“TMS”), an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 500,000 TMS treatments to over 14,000 patients struggling with depression.
October 20, 2020 – Toronto, ON –
GREENBROOK TMS ANNOUNCES DATES FOR ITS THIRD QUARTER 2020 FINANCIAL RESULTS
September 17, 2020 – Toronto, ON –
GREENBROOK TMS TO HOST INVESTOR WEBCAST ON SEPTEMBER 24, 2020
September 15, 2020 – Toronto, ON –
GREENBROOK TMS REACHES MILESTONE WITH MORE THAN 500,000 TREATMENTS